ACE-031 vs IGF-1

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

ACE-031 is a soluble decoy receptor fusion protein consisting of the extracellular domain of activin type IIA receptor (ActRIIA) linked to a human IgG1 Fc region, developed by Acceleron Pharma to bind and sequester myostatin, activin, and related TGF-beta superfamily ligands that negatively regulate muscle mass, with the goal of promoting muscle growth in severe wasting conditions including Duchenne muscular dystrophy. By competitively binding circulating myostatin and related ligands, ACE-031 reduces signaling through the Smad2/3 pathway that suppresses muscle satellite cell activation and protein synthesis; in preclinical models of myopathy, blockade of ActRIIA signaling produced significant increases in lean mass, supporting its evaluation in Phase 2 human trials. A Phase 2 randomized placebo-controlled trial in ambulatory boys with Duchenne muscular dystrophy demonstrated significant increases in lean body mass; however, the trial was halted early due to vascular-related adverse events including epistaxis and telangiectasias, attributed to off-target inhibition of angiogenic TGF-beta family ligands, and the Acceleron clinical program was subsequently discontinued. ACE-031 has no FDA approval and is not approved for any indication; commercial development was halted due to the adverse event signal identified in the clinical trial; it is not commercially available, and the vascular safety concern inherent to pan-ActRIIA ligand inhibition represents an unresolved risk that precludes its extrapolation to general performance or muscle enhancement applications.

Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake. Much shorter half-life (~15 min) than the LR3 analog (~20-30 hr) due to binding protein interactions.

IGF-1 (insulin-like growth factor 1; somatomedin C) is an endogenous 70-amino-acid polypeptide produced primarily in the liver in response to growth hormone signaling, functioning as the principal mediator of GH anabolic effects through its receptor (IGF-1R) expressed in virtually all tissues, with roles in muscle protein synthesis, bone growth, and cellular proliferation. IGF-1 activates IGF-1R tyrosine kinase to stimulate PI3K/Akt and MAPK/ERK signaling cascades, promoting protein synthesis, cell survival, and glucose uptake in muscle and bone; endogenous IGF-1 levels peak during puberty and decline with age, and GH-stimulating interventions exert many of their effects by elevating circulating IGF-1. The FDA-approved recombinant form, mecasermin (Increlex), is indicated for primary IGF-1 deficiency in children with GH receptor insensitivity syndrome, with multicenter controlled clinical trials demonstrating significant height velocity improvements in this rare pediatric population; this approved indication is specific to a defined hormonal insufficiency condition and is distinct from performance-enhancing or anti-aging uses of exogenous IGF-1. Research-grade IGF-1 is available as a compounded or gray-market compound used outside its approved indication; it is not approved for adult use or performance applications, and risks associated with IGF-1 excess — including effects on glucose homeostasis, potential oncogenic cell signaling, and acromegaly-related comorbidities — are relevant safety considerations for any off-label use.